Tecarini 40 mg and 5 mg, 80 mg and 5 mg, 40 mg and 10 mg, 80 mg and 10 mg FC tablets.
PDF Leaflet Revision Date: 27 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential hypertension.
Dosage (summary)
Starting dose: 40/5 mg once daily; max: 80/10 mg once daily.
Onset of Action / Duration
Onset: 3 hours, Duration: 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy or lactation.
Key Drug Interactions
- Potassium-sparing diuretics
- Lithium
- NSAIDs
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity to components
- Severe renal impairment
- Bilateral renal artery stenosis
- Severe hepatic impairment
- Pregnancy and lactation
Common side effects
- Dizziness
- Peripheral oedema
- Hypotension
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Caution when driving or operating machinery
Serious warnings
- Risk of hypotension in volume-depleted patients
- Dual blockade of RAAS contraindicated
Important Disclaimer
The Tecarini 40 mg and 5 mg, 80 mg and 5 mg, 40 mg and 10 mg, 80 mg and 10 mg FC tablets. professional information leaflet below is the property of Mylan and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
